Grants4Apps Accelerator 2016: You imagine, Bayer supports

BayerThe Grants4Apps (G4A) Accelerator developed by Bayer invites health IT and technology startups to apply for the program's 2016 edition. This year, Bayer looks primarily into projects aimed at fostering patient-doctor feedback in the Women's Health field as well as those improving patient engagement in Cardiology, Oncology, Radiology and Ophthalmology, but Bayer is also interested in highly innovative software, hardware, technologies applied to digital health fields.

The selected 5 start-ups will get free office space for 100 days at Bayer's Pharmaceuticals headquarters in Berlin, where representatives of Bayer senior management will offer them top-level coaching. In addition, Bayer will provide a financial support of 50,000 Euro to each of the startups.

For the third year in a row, the Grants4Apps Accelerator welcomes startups from around the world, whose software services, technologies, and apps have the potential of creating value for physicians and patients. Projects can be submitted by May 31st, 2016.

"Since 2014, IT and technology passionates from all over the world, with a focus on health projects, are invited to apply for what might become their biggest development opportunity. We are more than proud of the project's echo, especially at a local level, with Bucharest being the 2nd city in overall submissions in 2015. Furthermore, Romania ranked 6th in terms of number of submissions received from all over the world, which is outstanding. We are confident that the 2016 edition will suscitate at least as much interest and local bright ideas will improve people's lives," said Ruxandra Pirojoc, Head of Communications for Bayer Romania and Bulgaria.

"At Bayer, we strongly believe in the power of the local community - Scientists, Technologists, Engineers, and Mathematicians in Bucharest, working or willing to work on projects regarding digital health and digital farming. This is why we have established a group on meetup.com, aimed at fostering innitiave and cooperation between professionals, while also serving as a networking and discussions platform. It is a local innitiave matching Bayer’s vision of open innovation and global cooperation," added George Nancu, IT Specialist at Bayer Romania.

In June, an expert jury from Bayer will select the five winners who will be invited to spend 3.5 months in the Accelerator on the Bayer Pharmaceuticals headquarters in Berlin from August to December 2016. Aside from the financial support to help developing their business, the startups will be offered free co-working space, mentoring and expert advice on business development, market research, financial planning, and pitching for investors. The goal for the startups in the program is to further develop their product and business model so they can obtain financing from other sources after the program.

Application forms for startups are available at the Grants4Apps website http://www.grants4apps.com/berlin

Bayer fully embraces new approaches of open innovation, such as the "CoLaborator" or crowdsourcing initiatives like "Grants4Targets", "Grants4Indications", "Grants4Apps" and "PartnerYourAntibodies".

Bayer: Science for a Better Life
Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech polymer materials. As an innovation company, it sets trends in research-intensive areas. Bayer's products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2015, the Group employed around 117,000 people and had sales of EUR 46.3 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.3 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015.

Most Popular Now

Pfizer and Lilly announce top-line results from lo…

Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) announced top-line results from a Phase 3 study evaluating tanezumab 2.5 mg and 5 mg. The objective of the stu...

Bristol-Myers Squibb reports first quarter financi…

Bristol-Myers Squibb Company (NYSE:BMY) today reported results for the first quarter of 2019 which were highlighted by strong demand for Opdivo (nivolumab) and Eliquis (a...

AstraZeneca starts artificial intelligence collabo…

AstraZeneca and BenevolentAI today began a long-term collaboration to use artificial intelligence (AI) and machine learning for the discovery and development of new treat...

Comprehensive tumor profiling promises new therape…

The WINTHER trial, NCT01856296, led by investigators from Vall d'Hebron Institute of Oncology - VHIO (Spain), Chaim Sheba Medical Center (Israel) (Raanan Berger), Gustave...

Walnuts may help lower blood pressure for those at…

When combined with a diet low in saturated fats, eating walnuts may help lower blood pressure in people at risk for cardiovascular disease, according to a new Penn State ...

Amgen ignites a social fitness movement to support…

Amgen (NASDAQ:AMGN) launched the Breakaway Challenge initiative, a national social fitness program to motivate individuals to take action in their health and to support t...

Chemotherapy or not?

Case Western Reserve University researchers and partners, including a collaborator at Cleveland Clinic, are pushing the boundaries of how "smart" diagnostic-imaging machi...

Drugs to prevent stroke and dementia show promise …

Treatments that prevent recurrence of types of stroke and dementia caused by damage to small blood vessels in the brain have moved a step closer, following a small study...

Possible link between autism and antidepressants u…

An international team led by Duke-NUS Medical School has found a potential link between autistic-like behaviour in adult mice and exposure to a common antidepressant in t...

Personalizing precision medicine with combination …

Precision oncology often relies on treating patients with a single, molecularly matched therapy that targets one mutation in their tumor. In a report, published online in...

Researchers define Alzheimer's-like brain disorder

A brain disorder that mimics symptoms of Alzheimer's disease has been defined with recommended diagnostic criteria and guidelines for advancing future research on the con...

Amgen and Syapse enter precision medicine collabor…

Amgen (NASDAQ:AMGN), a world leader in biotechnology, and Syapse, a company powering precision medicine insights through its global provider network, announced a precisio...